Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Review By Dilip Davda on July 8, 2022
• HLAL is engaged in trading activities only.
• It is marketing raw milk, live chicken and agro products in two states.
• Based on FY22 consolidated earnings, this at-par issue is priced aggressively.
• Higher promoter stake dilution is a concern.
• Risk seeker/cash surplus investors may consider an investment.
ABOUT COMPANY:
Healthy Life Agritec Ltd. (HLAL) incorporated in the month of November 2019, is engaged in the business of trading Raw Milk in the state of Maharashtra and Live Chicken and Agro Products in the state of Maharashtra and Karnataka.
It procures raw cow milk from milk farmers in the State of Maharashtra, a significant cow milk-producing region in India. HLAL's direct procurement model enables it to control costs and ensure the quality of the raw milk procured. The company has engaged procurement partners, to coordinate the milk procurement process with milk farmers and supply Raw milk to milk wholesalers in the state of Maharashtra. In addition to Raw Milk, the company also procure Poultry from Poultry Growers in the state of Maharashtra and Karnataka and supplies poultry to Chicken Wholesalers in both states.
During 2021-22, it sold 39.20 Lakhs litres of raw Cow Milk and 7.69 Lakhs Kgs of Live Chicken which contributes approximately 60.05% and 39.95% of total revenue, while for 2020-21, it sold 6.50 Lakhs litres of raw Cow Milk and 1.21 Lakhs Kgs of Live Chicken which contributes approximately 59.95% and 40.05% of total revenue. As of the date of filing this offer document, it has 8 employees on its payroll.
ISSUE DETAILS/CAPITAL HISTORY:
To part finance its needs for working capital (Rs. 8.54 cr.) and general corporate purposes (Rs. 1.00 cr.), HLAL is coming out with a maiden IPO of 10000000 equity shares of Rs. 10 each at par to mobilize Rs. 10 cr. The issue is opening for subscription on July 13, 2022, and will close on 18.07.2022. Minimum application is to be made for 10000 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on BSE SME. The issue constitutes 45.43% of the post-IPO paid-up capital of the company. HLAL is spending Rs. 0.46 cr. for this IPO process.
The issue is solely lead managed by Finshore Management Services Ltd., Cameo Corporate Services Ltd. is the registrar to the issue and Nikunj Share Brokers Ltd. is the market maker for this IPO.
The company has issued its entire equity capital at par value so far. The average cost of acquisition of shares by the promoters is Rs. 10 per share.
Post-IPO, HLAL's current paid-up equity capital of Rs. 12.01 cr. will stand enhanced to Rs. 22.01 cr. Based on the IPO pricing, the company is looking for a market cap of Rs. 22.01 cr.
FINANCIAL PERFORMANCE:
On the financial performance front, while on a standalone basis, HLAL has reported turnover/net profits of Rs. 4.12 cr. / Rs. 0.07 cr. (FY21) and Rs. 26.16 cr. / Rs. 0.76 cr. (FY22). On a consolidated basis, it has posted a net profit of Rs. 0.83 cr. on a turnover of Rs. 33.96 cr. (FY22).
For the last three fiscals, on a standalone basis, HLAL has posted an average EPS of Rs. 25.23 and an average RoNW of 30.94% (based on the paid-up equity capital of respective years). The issue is priced at a P/BV of 0.92 based on its NAV of Rs. 10.82 as of March 31, 2022, and at a P/BV of 0.96 based on its post-IPO NAV of 10.37 per share.
If we attribute its consolidated FY22 earnings on post IPO fully diluted equity, then the asking price is at a P/E of 26.31 making it an aggressively priced IPO despite being at par.
DIVIDEND POLICY:
HLAL has not declared any dividend for the reported periods of accounting in the offer document. It will adopt a prudent dividend policy post listing, based on its financial performance and future prospects.
COMPARISON WITH LISTED PEERS:
As per the offer document, HLAL has no listed peers to compare with.
MERCHANT BANKER'S TRACK RECORDS:
This is the 25th mandate from Finshore Management in the last five fiscals (including the ongoing one). Out of the last 10 listings, 2 opened at par and the rest with premiums ranging from 0.09% to 65.50% on the day of listings.
Review By Dilip Davda on July 8, 2022
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.
About Dilip Davda
Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.
Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.
(Dilip Davda -SEBI registered Research Analyst-Mumbai,
Registration no. INH000003127 (Perpetual)
Email id: dilip_davda@rediffmail.com ).
The initial public offer (IPO) of Healthy Life Agritec Limited offers an early investment opportunity in Healthy Life Agritec Limited. A stock market investor can buy Healthy Life Agritec IPO shares by applying in IPO before Healthy Life Agritec Limited shares get listed at the stock exchanges. An investor could invest in Healthy Life Agritec IPO for short term listing gain or a long term.
Read the Healthy Life Agritec IPO recommendations by the leading analyst and leading stock brokers.
Healthy Life Agritec IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Healthy Life Agritec IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.
Our recommendation for Healthy Life Agritec IPO is to subscribe for long term.
As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe for long term to the Healthy Life Agritec IPO.
The Healthy Life Agritec IPO allotment status will be available on or around July 21, 2022. The allotted shares will be credited in demat account by July 25, 2022. Visit Healthy Life Agritec IPO allotment status to check.
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
